GenMark Diagnostics to Participate in the Cowen 41st Annual Health Care Conference
GenMark Diagnostics (NASDAQ: GNMK), a leader in automated multiplex molecular diagnostics, announces participation in the Cowen 41st Annual Health Care Conference on March 1, 2021, at 2:00 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
GenMark Diagnostics (NASDAQ: GNMK), a leader in automated multiplex molecular diagnostics, announces participation in the Cowen 41st Annual Health Care Conference on March 1, 2021, at 2:00 p.m. ET. The event will be virtual, and interested parties can access the live and archived webcast on their investor relations site.
GenMark specializes in enhancing patient care and reducing healthcare costs through its proprietary eSensor® technology. Their systems, such as the eSensor XT-8® and ePlex®, address diverse infectious disease testing needs.
Details
News Market Reaction – GNMK
The recorded move for GNMK in the trading session of this news was +0.32%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CARLSBAD, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in the upcoming Cowen 41st Annual Health Care Conference.
GenMark’s management team is scheduled to present in a virtual setting on Monday, March 1st, 2021 at 2:00 p.m. ET. Interested parties can access the live and archived webcast at ir.genmarkdx.com
ABOUT GENMARK
GenMark Diagnostics (NASDAQ: GNMK) is a leading provider of multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care. Utilizing GenMark’s proprietary eSensor® detection technology, GenMark’s eSensor XT-8® and ePlex® systems are designed to support a broad range of molecular diagnostic tests with compact, easy-to-use workstations and self-contained, disposable test cartridges. GenMark’s ePlex: The True Sample-to-Answer Solution™ is designed to optimize laboratory efficiency and address a broad range of infectious disease testing needs, including respiratory, bloodstream, and gastrointestinal infections. For more information, visit genmarkdx.com
Investor Relations Contact
Leigh Salvo
(415) 937-5404
ir@genmarkdx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.